The endothelin (ET) receptor mediating relax ation of cerebral arteries was characterized using ring segments obtained from the rat basilar artery. Under rest ing tension, ET-3 (>10-8 M) but not the specific ETB receptor agonist IRL 1620 induced contraction. In ring segments pre contracted with 3 x 10-6 M prostaglandin (PG) F2a, ET-3 00-1 2 -10-8 M) and IRL 1620 (10-14_ 10-6 M) induced concentration-related relaxation. IRL 1620 was more potent than ET-3, the pDz (-logIOEC 5 0) values being 10.002 ± 0.751 (mean ± SD) for IRL 1620 and 8.836 ± 0.415 for ET-3. Relaxation was abolished after preincubation with the nitric oxide (NO) synthase inhibitor ,vG-nitro-L-arginine (10-5 M) as well as in seg ments devoid of a functionally intact endothelium. At a
The vasomotor tone of arteries is governed by a number of stimuli derived from different sources including the vessel wall itself, the plasma, and the surrounding parenchymal tissue. Among the com ponents located in the vessel wall, the endothelial cells play an important role by releasing relaxant as well as contractile factors under basal conditions or upon stimulation (Furchgott and Vanhoutte, 1989) . One of the endothelium-derived relaxing factors has been identified as nitric oxide (NO) (Ignarro et aI., 1987; Palmer et aI., 1987) or a NO-containing com pound (Myers et aI., 1990) derived from the precur sor L-arginine by the enzyme NO synthase. The most prominent endothelium-derived contracting concentration above 10-8 M, ET-3 resulted in a further increase of PGF2a-induced contraction that was not ob served with IRL 1620. The presumably specific ETB re ceptor antagonist IRL 1038 (10-7-3 x 10-6 M) dimin ished or even abolished (3 x 10 -6 M) the relaxation in duced by ET-3 or IRL 1620. IRL 1038 did not exert any vasomotor effect by itself, and it did not significantly af fect ET-3-induced contraction. These results indicate that in the rat isolated basilar artery, the ET-3-induced relax ation is probably due to activation of an ET B-type recep tor located on the endothelial cells and mediated by re lease of nitric oxide. Key Words: Basilar artery Endothelin-Endothelium-dependent relaxation-ET B receptor-In vitro. factor appears to be endothelin (ET) 1, which was discovered by Yanagisawa et ai. (1988) . ET-l is a 21-amino-acid polypeptide and has a high degree of structural homology with the other members of the ET family, ET-2 and ET-3 (Doherty, 1992) . Al though NO and ET have initially been identified as endothelium-derived factors, both of them may be synthesized and released from brain parenchymal cells as well (for review see Ehrenreich and Schil ling, 1994) .
The relaxant action of NO depends on the acti vation of the soluble guanylate cyclase resulting in an increase of cyclic GMP content in the vascular smooth muscle cells, while the ETs exert their va somotor effects by activating specific G-protein coupled receptors. Based on pharmacological stud ies, two subtypes of ET receptors were identified originally (Maggi et aI., 1989) . The ETA receptor is characterized by a higher affinity toward ET -1 than ET -3, while the ET B receptor is nonselective, i.e., displays a similar affinity toward ET-l and ET-3 (Haynes et aI., 1993) . The ETA receptor, which ob-viously mediates contraction, has been located on the vascular smooth muscle cells (Adner et aI., 1993; Salom et aI., 1993; Feger et aI., 1994) , while the ET B receptor, which may induce relaxation, ap pears to be located on the endothelial cells as sug gested in studies performed in rat aorta (Sudjarwo et aI., 1992; Karaki et aI., 1993a,b) .
Recently, new compounds have become avail able acting as specific ETA antagonists, such as BQ-123 (Ihara et aI., 1992) and FR 139317 (Aramori et aI., 1993) , or as ETB agonists and antagonists, such as IRL 1620 and IRL 1038, respectively (Takai et aI., 1992; Urade et aI., 1992; Karaki et aI., 1993a,b) . With use of these compounds, the ET receptor sub types mediating contraction and relaxation have been further characterized in different vascular and nonvascular preparations. These studies have par tially confirmed the original classification, but they have also provided evidence for the presence of ad ditional contractile and relaxant ET receptor sub types (Moreland et aI., 1992; Cardell et aI., 1993; D'Orleans-Juste et aI., 1993; Sudjarwo et aI., 1993; Gray et aI., 1994; Hori et aI., 1994) .
In cerebral blood vessels such as the basilar and middle cerebral artery, the contractile action of ETs has been attributed to activation of ETA receptors solely (Adner et aI., 1993; Salom et aI., 1993; Feger et aI., 1994) . The presence of ET B receptors has not been demonstrated unequivocally as yet, although dilatation of rat basilar artery during superfusion with IRL 1620 was described in a preliminary article (Kitazono et aI., 1994) . A small relaxant component of ET -1 has been reported in two studies in vivo only (Armstead et aI., 1989; Faraci, 1989) , not in vitro. We have recently found a relaxant action of ET-3 in the isolated rat basilar artery (Feger et aI., 1994) . This relaxation was abolished by preincuba tion with � -nitro-L-arginine (NOLAG) to block NO synthase, suggesting involvement of NO. On the basis of this finding, the aim of the present study was to characterize the receptor subtype underlying the ET-3-induced relaxation of the isolated rat bas ilar artery using the ET B-specific agonist IRL 1620 and the ETB receptor antagonist IRL 1038.
MATERIALS AND METHODS

Drugs
ET-3 from Peninsula (Heidelberg, Germany), IRL 1620 [suc-(Glu9 ,Ala II, 1 5 )-endothelin-l(8-20] and IRL 1038 [(Cysll-Cys 1 5 )-endothelin-l(11-21)] from Alexis (Uiufelf ingen, Switzerland), 5-hydroxytryptamine creatinine sul fate (5-HT), acetylcholine chloride (ACh), histamine di hydrochloride, NOLAG, and dimethyl sulfoxide from Sigma (Deisenhofen, Germany), and prostaglandin (PG) F2a tromethamine salt from Paesel and Lorei (Frankfurt, J Cereb Blood Flow Metab, Vol. 15, No.4, 1995 Germany) were used. Stock solution of ET-3 was dis solved and diluted in sterile bidistilled water. Stock solu tions of IRL 1620 (10-4 M) and IRL 1038 (3 x 10-4 M) were prepared in 1 and 30% dimethyl sulfoxide, respec tively, and diluted in sterile distilled water, while the other compounds were made up in 0.9% NaCl. All solu tions were prepared freshly on each day of experiment and kept on ice throughout.
Animal preparation
Male Wistar rats (180-350 g) obtained from Charles River (Sulzfeld, Germany) were used throughout. Animal preparation was performed as described previously (Feger et al., 1994) . Briefly, the animals were bled from the carotid arteries under ether anesthesia, The brains were quickly removed and placed in ice-cold modified Krebs-HogesHitt solution (mmol/L): NaCl, 119; KCl, 4.6; NaH2P0 4 , 1.2; CaCl2 . 2H20, 1.5; MgCl2 • 6H20, 1.2; NaHCO), 15; glucose, 10. The basilar artery was isolated under a binocular microscope and transferred into 5-ml organ baths. The arteries were cut into ring segments (three to four from each animal) and mounted on two L-shaped metal threads of 70-f,Lm diameter each (Parsons et aI., 1991) , One thread was fixed to the bath, and the second one was connected to a force transducer (Ql1; Hottinger Baldwin, Darmstadt, Germany) for measuring isometric force. The signal was amplified (MGT 233; Hot tinger Baldwin) and given on a multichannel pen recorder (Kipp & Zonen, Solingen, Germany). The Krebs solution was continuously bubbled with 90% 02/10% CO2 to main tain a pH of 7.25-7.3 (Feger et aI., 1994) . In some exper iments the endothelium was removed after mounting by gently rubbing the inner surface with a hair of the head (Osol et aI., 1989) or an eyelash.
Experimental protocol
After mounting, the vessels were allowed a 90-min equilibration period with warming up the organ bath to 37°C and repeated washing every 10-15 min. The resting tension was adjusted to 2.5-3.5 mN. After the equilibra tion period, the segments were precontracted with 5-HT (10-6 M), and on top of precontract ion, ACh (10-8-10-4 M) was cumulatively applied. Vessels without rubbing that displayed relaxation to ACh of >25% of precontrac tion were considered to have a functionally intact endot helium (E + ). After rubbing, no clear-cut relaxation upon application of ACh and a maximum decrease of 15% of precontraction during application of ACh were accepted to indicate complete damage of the endothelium but pre served smooth muscle function (E -). Each preparation received a K + -rich (124 mM) Krebs solution (NaCI sub stituted by KCl) to obtain a reference contraction. Only segments that developed >2 mN force to K + -Krebs in vessels with intact endothelium and 1.5 mN force to K + -Krebs in endothelium-denuded segments were used in the present study.
After obtaining the reference contraction and allowing another 45-min rest, the effects of cumulatively applied ET-3 (10-1 2 _10-7 M) and IRL 1620 (10-14_10-6 M) were investigated after precontraction with PGF2a (3 X 10-6 M). In some experiments ring segments (E + ) were pre incubated with NOLAG (10-5 M) for 20-30 min before precontraction with PGF2a to block NO synthase and thus release of NO. The effect of the presumable ETB receptor antagonist IRL 1038 was examined in vessels that were incubated with IRL 1038 (10-7-3 X 10-6 M) for 20 min before precontraction with PGF2a and application of ET-3 or IRL 1620. To test the specificity of IRL 1038, the relaxation induced by ACh (10-8_10-4 M) or histamine (10-8-10-4 M) after incuba tion with IRL 1038 (3 x 10-6 M) was studied in some segments. In addition, the effect of IRL 1038 (3 x 10-6 M) upon the contractile action of ET-3 under resting ten sion was also investigated. Only one concentration response curve for either ET-3 or IRL 1620 was per formed in each segment.
Analysis of results
All results are expressed as means ± SD. The contrac tile effect of ET-3 was calculated as percentage of refer ence contraction (induced by 124 mM K + -Krebs solu tion), while the relaxant responses were computed as per centage decrease of PGF2a-induced precontraction. The pD2 value (-log I OEC 5 0, that concentration that induces half-maximal relaxation) was determined for individual concentration-response curves by linear regression after logarithmic transformation of the concentrations below and above the EC so' For statistical evaluation, one-way analysis of variance was performed followed by Tukey's honestly significant difference multiple range test for in dividual comparisons. A p value of <0.05 was taken to indicate significance.
RESULTS
PGF2o: (3 X 10-6 M) induced comparable con traction in ring segments with and without function ally intact endothelium (E + : 2.2 ± 1.0 mN, n = 29; E-: 2.5 ± 1.1 mN, n = 17). Furthermore, PGF2o: induced contraction was not significantly altered in the presence of NOLAG (10-5 M) (2.0 ± 1.7 mN, n = 26), which per se caused a marked increase in resting tension (2.6 ± 1.8 mN, n = 26). ET-3 in duced a concentration-related relaxation below 10-8 M, while at higher concentrations, PGF2 uinduced precontraction was increased (Fig. 1) . The relaxant action of ET-3 was dependent on the pres ence of an intact endothelium since it was abolished in ring segments after rubbing (Fig. 1) . Similarly, ET-3-induced relaxation of E + segments was sup pressed in the presence of 10-5 M NOLAG (Fig. 1) , indicating mediation by release of NO.
Similar to ET-3, the ETB receptor agonist IRL 1620 induced a concentration-related relaxation as shown in Fig. 2 . However, IRL 1620 was more po tent and efficient than ET-3 (Table 1 ). In accor dance with the results obtained for ET-3, IRL 1620induced relaxation was abolished in the presence of 10-5 M NOLAG and after rubbing (Fig. 2 ). In con trast to the results obtained with ET-3, there was never any increase above the level of precontrac tion observed following application of IRL 1620.
To further characterize the receptor subtype un derlying ET-3-induced relaxation, the action of the putative ETB receptor antagonist IRL 1038 was studied in E + vessels. IRL 1038 (10-7 -3 x 10-6 M) Given are means ± SD of 11-19 observations. Relaxation by �1O-10 M ET-3 is significantly different in the presence of NOLAG vs. control and �1O -9 M ET-3 in E vessels versus control (Tukey honestly significant different test).
did not induce any relaxation per se, but diminished ET -3-induced relaxation in a concentration-related manner as shown in Fig. 3 . In the presence of 3 x 10-6 M IRL 1038, the relaxation induced by ET-3 and IRL 1620 was abolished (Table 1 ; Figs. 3 and 4) . The contractile action of ET-3 (> 10-8 M) was not affected in the presence of IRL 1038 (Fig. 3) . To prove the selectivity of IRL 1038, its effects on ACh-and histamine-induced relaxation were tested in separate experiments after precontracting the ring segments with 10-6 M 5-HT. Both compounds elicited a concentration-related relaxation in the presence of 3 x 10-6 M IRL 1038 with the maxi mum values being unaltered [ACh: control, 47.9 ± 11.4% (n = 6) vs. 47.1 ± 11. 7% in the presence of IRL 1038 (n = 18), p > 0.05; histamine: > 100% in the absence and presence of IRL 1038 (n = 6 each)). When IRL 1620 was applied on vessel segments under resting tension, there was no contractil� ac tion at all (results not shown). In contrast, ET-3 induced a concentration-related contraction as shown previously (Feger et al., 1994) . The contrac tile action started at a lower concentration in the Given are means ± SD of 11-16 observations. Relax ation by �3 x 10-1 2 M IRL 1620 is significantly different in the presence of NOLAG vs. control and E -vessels versus control (Tukey honestly significant difference test).
presence of 3 x 10-6 M IRL 1038 (Fig. 5 ), although this shift did not reach statistical significance. The maximum contraction achieved with ET-3 was not affected by IRL 1038.
DISCUSSION
ET-l was originally described as a potent vaso constrictor agent (Yanagisawa et aI., 1988) , but re laxant effects of ET-l and ET-3 have also been ob served in the systemic circulation in vivo (DeNucci et aI., 1988) and in peripheral arteries in vitro (Sud jarwo et aI., 1992; Karaki et aI., 1993a,b) . In con trast, there is hardly any information on a relaxant action of ETs in the cerebral circulation. Cerebroar terial dilatation by ETs has been observed occa sionally in vivo (Armstead et aI., 1989; Faraci, 1989) but not in vitro. We have recently described ET-3induced relaxation of the isolated rat basilar artery precontracted with 5-HT (Feger et ai., 1994) . This observation has now been confirmed using PGF2o: for precontraction. The receptor underlying ET-3induced relaxation was characterized in the present study as an ET B subtype located on the endothelial cells.
J Cereb Blood Flow Metab. Vol. 15, No.4, 1995 PGF2o: was used for precontraction since under this condition ET-3 induced a significantly more pronounced relaxation than in segments precon tracted with 5-HT (Feger et aI., 1994) . The reason for the difference is not yet clear, but may be due to additional effects of NO besides stimulation of sol uble guanylate cyclase. Thus, a relaxant action of NO may result from a direct interaction with the contractile prostanoid receptor or the receptor transduction coupling mechanism similar to that de scribed recently for the N-methyl-o-aspartate sub type of the glutamate receptor (Manzoni et al., 1992) and even the ETA receptor (Goligorsky et aI., 1994) .
The conclusion that the relaxant ET receptor is obviously located on the endothelial cell membrane is based mainly on the experiments with ring seg ments in which the endothelium was mechanically destroyed as indicated by the loss of ACh-induced relaxation. In these deendothelialized segments, the relaxant effect of ET-3 and IRL 1620 was also largely abolished, although a small decrease of PGF2o:-induced contraction was noted in some seg ments. This decrease of precontraction occurred more or less continuously (i.e., was obviously not related to the application of the test compounds) and may thus well reflect a spontaneous loss of tone independent of the ET-3 or IRL 1620 applied.
Further evidence for the endothelial location of the relaxant ET receptor is provided by the obser vation that NOLAG, a specific inhibitor of the NO synthase (Miilsch and Busse, 1990) , abolished ET-3-and IRL 1620-induced relaxation in E + seg ments. In fact, there was even a small increase in tone during application of low concentrations of ET-3 and IRL 1620 ( Figs. 1 and 2) . This increase in tone was probably not due to a direct effect of ET-3 or IRL 1620, as concluded from control experi ments in which only the solvent for ET-3, bidistilled water, was applied to segments pre incubated with NOLAG. In these experiments, an increase in PGF2o:-induced tone occurred, suggesting a pro longed contractile action of NOLAG as the under lying mechanism.
The classification of the relaxant ET receptor as an ET B subtype is based on two observations. First, IRL 1620, which has been described as a specific ET B receptor agonist (Takai et aI., 1992; Karaki et aI., 1993b) , induced a concentration-related relax ation similar to ET-3. It was �15 times more potent than the mixed ETB/ETA receptor agonist ET-3. Second, relaxation induced by ET-3 and IRL 1620 could be antagonized by preincubation with IRL 1038, which has been described as an ET B-specific antagonist (Urade et aI., 1992; Karaki et aI., 1993a) . (11) 25.8 ± 13.9 (1 1) 9.329 ± 0.231a (8) 42.9 ± 12.5 (8) 8.785 ± 0.495 (4) 21.8 ± 22.2 (6) 9.231 ± 0.474a (7) 38.4 ± 18.6 (7) 3 X 10-.-6 M
Complete blockade Complete blockade
Emax is given as % of precontract ion of prostaglandin F2a (3 X 10-6 M). Given are means ± SD with the number of observations in parentheses.
a p < 0.05 vs. control.
The specificity of IRL 1038 was tested in the present study, and it was found not to affect ACh induced relaxation, which is endothelium depen dent (Schilling et aI., 1990) , or histamine-induced relaxation, which is endothelium independent, in rat basilar artery (Chang et aI., 1988) . Although the literature on the specificity of the IRL agonist and antagonist is not unequivocal, our present data sug gest that the relaxation is probably mediated by an ET B receptor.
In the presence of IRL 1038, the contractile ac tion of ET-3 applied on vessel segments under rest ing tension or after precontraction with PGF2a was not affected. The contraction induced by ET-3 is most probably due to activation of ETA receptors as suggested previously (Feger et aI., 1994) . In con trast to ET-3, IRL 1620 did not induce any contrac tion, either under resting tension (unpublished ob servations) or after PGF2a precontraction. These results suggest the absence in the rat basilar artery of a contractile ET B or ET B-like receptor. Evidence for the presence of such a contractile ET receptor subtype has been provided in several peripheral ar teries and veins (Cardell et aI., 1993; D'Orleans-Juste et aI., 1993; SUdjarwo et aI., 1993; Gray et aI., 1994) . In the present study, the existence of a relaxant ET B receptor that induces release of NO has clearly been shown. From these results, the question arises of whether ET -I-induced dilatation of pial arteries (Armstead et aI., 1989; Faraci, 1989 ) and increase in regional cerebral blood flow (Kobari et aI., 1994) are due to activation of this ET receptor subtype. The mechanism(s) of action of ETs is of potential therapeutic interest since an increased release of ETs from vascular and nonvascular sources along with a decrease of NO, which constitutes a natural opponent , has been hypothesized as an important factor in the de velopment of cerebral vasospasm. Inhibiting the ETA-induced contraction while preserving the ET B mediated relaxation may thus be a new approach for the treatment of vasospasm.
